{"id":"W2597509495","doi":"10.1200/jco.2012.30.15_suppl.4113","title":"SWOG 0941: A phase II study of sorafenib and erlotinib in patients (pts) with advanced gallbladder cancer or cholangiocarcinoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Sorafenib; Erlotinib; Gallbladder cancer; Clinical endpoint; Gastroenterology; Oncology; Progressive disease; Gallbladder; Phases of clinical research; Cancer; Progression-free survival; Performance status; Surgery; Epidermal growth factor receptor; Toxicity; Chemotherapy; Clinical trial; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002749872,0.001730844,0.002716661,0.0005493284,0.0004473826,0.0009275047,0.0008479455,0.001320897,0.005156653],"category_scores_gemma":[0.001061798,0.0009208131,0.001285493,0.0007495403,0.001192518,0.0008626793,0.0005614453,0.002815627,0.001466434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00102895,"about_ca_system_score_gemma":0.002985529,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001228356,"about_ca_topic_score_gemma":0.003101162,"domain_scores_codex":[0.9992974,0.0004227691,0.00004100122,0.00006760984,0.00004982826,0.0001214246],"domain_scores_gemma":[0.999268,0.0001065406,0.0001100557,0.00004559119,0.00003719434,0.0004326167],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.750979,0.07120135,0.01736293,0.001939342,0.001537154,0.0007034139,0.0004773246,0.002752228,0.02934932,0.0004086837,0.007999834,0.1152894],"study_design_scores_gemma":[0.7087747,0.2691229,0.014449,0.00004033268,0.0004374822,0.0005221003,0.00007815861,0.001071467,0.001295687,0.0001427107,0.004034264,0.00003119924],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991113,0.001872947,0.0003842782,0.0005210427,0.0001271765,0.003090719,0.001297141,0.00008663408,0.001507148],"genre_scores_gemma":[0.9780051,0.003024043,0.002666564,0.001489553,0.0002461118,0.006724086,0.004265639,0.00004739093,0.003531599],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005156653,"threshold_uncertainty_score":0.01725078,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1193045961653972,"score_gpt":0.4677784698520907,"score_spread":0.3484738736866936,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}